The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2017 | The BIRCH trial data discussed by Dr Peters
Solange Peters, MD, PhD from the University of Lausanne, Lausanne, Switzerland discusses the latest data from the Phase II BIRCH trial, which investigated the outcomes of patients with non-small cell lung cancer (NSCLC). Patients involved in the trias received immunotherapy as a first-line treatment and the correlation between PD-L1 expression and patient response was investigated. This interview was recorded at the annual meeting of European Lung Cancer Conference (ELCC) 2017 in Geneva, Switzerland.
